Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either ipilimumab or high-dose interferon after surgery.
from Medindia Health News https://ift.tt/3uTH0Wv
No comments:
Post a Comment